Table 3 Cost-effectiveness results – base-case analysis
Long-acting stimulant monotherapy | GXR + long-acting stimulant | Incrementala | |
|---|---|---|---|
Average QALYs | 0.627 | 0.655 | 0.028 |
Patient-weeks with response | 12.46 | 19.03 | 6.57 |
Drug costs, $CA | 337 | 1,072 | 735 |
Medical costs, $CA | 612 | 545 | −67 |
Productivity losses, $CA | 2,633 | 2,299 | −334 |
Total cost, $CA MoH perspective | 949 | 1,617 | 668 |
Total cost, $CA Societal perspective | 3,582 | 3,915 | 334 |
Incremental cost/QALY, $CA MoH perspective | $CA23,720/ QALY | ||
Incremental cost/QALY, $CA Societal perspective | $CA11,845/QALY | ||
Incremental cost/patient-week with response, $CA MoH perspective | $CA102/responder | ||
Incremental cost/patient-week with response, $CA Societal perspective | $CA51/responder |